ReviewBiophysical reviews2025
Recent progress in probing small molecule interactions with DNA.
Review in Biophysical reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Synthesis, structural characterization, and dual DNA/HSA binding of novel Palladium(II) violurate complex with selective p53/Caspase-3-mediated anticancer activity.Scientific reports · 2026Article
- DNA-Binding Properties of Iridium(III) Complexes Encompassing Design, Function and Biophysical Assessments.Chemphyschem : a European journal of chemical physics and physical chemistry · 2026Review
- 1950-2000: five decades of curiosity-driven discovery in alternative DNA structures.Nucleic acids research · 2026Article
- Copper(II)-5-chloro-2-hydroxybenzophenone Complexes withACS omega · 2026Article
- Vision of Life's Code: Molecular Probe Nanoarchitectonics for Deep RNA/DNA Illumination.ACS nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acids are primary therapeutic targets, and understanding drug-DNA interactions is essential to the discovery of new clinical agents. In recent years, the desire to develop therapies with specific biological targets has produced new molecules that preferentially interact with complex nucleic acid sequences and structures. As such, the targeting of non-canonical nucleic acids, including DNA triplexes, G-quadruplexes, i-motifs, three-way junctions and Holliday junctions, have emerged due to their roles in gene regulation, genome stability and cellular stress responses. Characterising the interactions of these non-canonical structures with new ligands and metal complexes has led to the discovery of promising agents with therapeutic potential. Biophysical techniques including spectroscopic methods, crystallography and biomolecular assays have been critical to probing these interactions. This review describes recent advancements in the analysis of higher-order drug-DNA interactions for the rational design of targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.